FDA Approves Novartis' Cosentyx To Treat Plaque Psoriasis In Pediatric Patients

Secukinumab (Cosentyx®) • Johns Hopkins Arthritis Center

COSENTYX® (Secukinumab) Dermatology SensoReady® 150mg Injection Video | Novartis UK HCP Portal

Long-Term Safety and Efficacy of Secukinumab in Treatment of Spondyloarthropathies

Impact of Secukinumab and Adalimumab on Novel Mortality NMR-Derived Multimarkers in Patients with Psoriasis: Analyses From Two Randomized Placebo-Controlled Trials (Late Breaking)